Jade Biosciences (Nasdaq: JBIO), a San Francisco-based clinical-stage biotechnology company, has dosed the first participant in a first-in-human Phase I clinical trial of JADE201, a half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFF-R). The Jade Biosciences Phase I trial is enrolling participants with rheumatoid arthritis (RA) in a randomized, placebo-controlled, single ascending dose design, with interim data expected in 2027.
The trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics, with key biomarkers including BAFF-R occupancy, soluble BAFF levels, and B cell profiling. Jade said interim Phase I data in RA will inform indication prioritization across multiple autoimmune diseases supported by BAFF-R biology.
BAFF-R is the primary receptor through which B cell activating factor (BAFF) delivers pro-survival signals to mature B cells, activating both classical and non-canonical NF-κB pathways and driving expression of anti-apoptotic proteins including Bcl-2. In autoimmune diseases, BAFF is chronically overexpressed, sustaining autoreactive B cells that would otherwise be eliminated through peripheral tolerance mechanisms. This overexpression has been documented across SLE, Sjögren's syndrome, and RA, where elevated BAFF levels correlate with autoantibody production and disease activity.
Current B cell-directed therapies address this biology only partially. Rituximab, the established anti-CD20 agent used in RA after failure of conventional and biologic disease-modifying therapies, depletes circulating B cells but does not reach tissue-resident populations effectively, and plasma cells — the long-lived autoantibody-secreting cells responsible for sustained pathology — do not express CD20 and are therefore spared. Belimumab, approved for SLE, neutralizes soluble BAFF but does not directly kill B cells, limiting the depth of depletion achievable. JAK inhibitors, while broadly immunosuppressive, carry FDA black box warnings for cardiovascular events, malignancy, and thrombosis that constrain their use in older or higher-risk patients.
JADE201's design attempts to address these limitations through two simultaneous mechanisms. As an anti-BAFF-R antibody, it blocks the survival signal that sustains autoreactive B cells. As an afucosylated antibody — meaning the fucose residue has been removed from the Fc region — it binds FcγRIIIa on NK cells and macrophages with substantially higher affinity, driving enhanced antibody-dependent cellular cytotoxicity and phagocytosis. Preclinical studies demonstrated dose-dependent BAFF-R occupancy and sustained B cell depletion in non-human primates. The half-life extension is intended to support infrequent subcutaneous dosing, a potential convenience advantage over rituximab's intravenous regimen.